Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections

Abstract

Multiple myeloma (MM) patients mount suboptimal neutralizing antibodies (nAb) following 2-doses of SARS-CoV-2 mRNA vaccines. Currently circulating SARS-CoV-2 variants of concern (VOC) carry the risk of breakthrough infections. We evaluated immune recognition of current VOC including BA.1, BA.2 and BA.5 in 331 racially representative MM patients following 2 or 3 doses of mRNA vaccines. Third dose increased nAbs against WA1 in 82% but against BA variants in only 33-44% of patients. Vaccine-induced nAbs correlated with RBD-specific class-switched memory B cells. Vaccine-induced spike-specific T-cells were detected in patients without seroconversion and cross-recognized variant-specific peptides but were predominantly CD4+ T-cells. Detailed clinical/immunophenotypic analysis identified features correlating with nAb/B/T cell responses. Patients who developed breakthrough infections following 3 vaccine doses had lower live-virus nAbs, including against VOC. MM patients remain susceptible to SARS-CoV-2 variants following 3 vaccine doses and should be prioritized for emerging approaches to elicit variant-nAb and CD8+ T-cells.

SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study

“…We also evaluated cellular immunity with a novel immune repertoire profiling technique but note that it does not assess functional responses, how the results correlate with protection from severe disease is unknown, and some studies suggest that mRNA vaccines primarily induce CD4 + T-cell responses. 8 , 39 …”

Immune status and selection of patients for immunotherapy in myeloma: a proposal

“…The impact of these differences in immune fitness and response to immune intervention was recently illustrated in studies documenting high variance in humoral and cellular immune response to severe acute respiratory syndrome coronavirus 2 vaccines in MM. 54 , 55 Variance in immune status can not only affect response to therapy but also other outcomes including overall survival and risk of infections in patients with MM.…”

Role of B cells in immune‐related adverse events following checkpoint blockade

“…These features, along with early alterations in this specific B cell subset in patients developing irAEs following ICB 27 strongly support a role for these cells in the pathogenesis of irAEs. Although understudied, the proportion of these cells may also be impacted by underlying racial background, with higher proportion in Black patients 20,27 …”

“…Although understudied, the proportion of these cells may also be impacted by underlying racial background, with higher proportion in Black patients. 20,27 The role of B cells in human autoimmunity has long been supported by the well-documented correlation between organ/ tissue-specific antibodies even in the preclinical phase and the development of specific clinical autoimmune states. In some instances, the detection of these antibodies forms a part of the diagnostic criteria for clinical autoimmunity.…”